on OXURION (EBR:OXUR)
Oxurion in Exclusive Talks to Acquire Eclevar's Business and Assets
Oxurion NV, based in Leuven, Belgium, has announced exclusive negotiations to acquire Eclevar, a French CRO specializing in the MedTech sector. This strategic move aims to enhance Oxurion's platform across clinical and regulatory services in life sciences. Eclevar aligns with Oxurion's ambition to meet Europe's evolving regulatory standards and develop robust clinical data to support new and existing medical devices.
Established over the last 4.5 years, Eclevar has expanded its footprint internationally, generating €2.9 million in revenue in 2025. The acquisition is structured to integrate Eclevar's operating business into a new MedTech CRO platform, with Oxurion owning 68% and committing €250,000 for its development.
The company aims to finalize the acquisition by December 31, 2026, pending definitive agreements and usual closing conditions. Key figures from both companies anticipate operational synergies, leveraging combined expertise for growth and innovation in the MedTech CRO market.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all OXURION news